Somaxon Pharmaceuticals, Inc, has received a Complete Response Letter from the US FDA for its New Drug Application for Silenor (doxepin) for the treatment of insomnia. Based on its review, the FDA has determined that the NDA cannot be approved in its present form.
The details can be read here.
No comments:
Post a Comment